HER2 testing in malignant effusions of metastatic gastric carcinoma: Is it feasible?

Diagnostic Cytopathology

Volumn 43, Issue 1, 2015, Pages 80-85

  Wong, Daniel D ^a   Bastiaan De Boer, W ^a,b   Platten, Michael A ^a   Jo, Vickie Y ^c,d   Cibas, Edmund S ^c,d   Priyanthi Kumarasinghe, M ^a,b  

^a PATHWEST LABORATORY MEDICINE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cytology; Gastric cancer; HER2; Herceptin; Malignant effusions

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ASCITES FLUID; CARCINOMA; FEASIBILITY STUDY; FEMALE; GENETICS; HUMAN; MALE; MALIGNANT PLEURA EFFUSION; METABOLISM; MIDDLE AGED; NEOPLASM METASTASIS; PATHOLOGY; STOMACH NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; CARCINOMA; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PLEURAL EFFUSION, MALIGNANT; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84918587663     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.23212     Document Type: Article

References (23)

1. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D,. GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide: IARC cancer base no.10. Lyon, France: International Agency for Research on Cancer; 2010.
2. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
3. Ross JS, Fletcher JA,. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol 1999; 9: 125-138.
4. Yonemura Y, Ninomiya I, Yamaguchi A, et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 1991; 51: 1034-1038.
5. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology 2008; 52: 797-805.
6. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
7. Albarello L, Pecciarini L, Doglioni C,. HER2 testing in gastric cancer. Adv Anat Pathol 2011; 18: 53-59.
8. Hechtman JF, Polydorides AD,. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: A review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med 2012; 136: 691-697.
9. Martin JK, Jr, Goellner JR,. Abdominal fluid cytology in patients with gastrointestinal malignant lesions. Mayo Clin Proc 1986; 61: 467-471.
10. Fox SB, Kumarasinghe MP, Armes JE, et al. Gastric HER2 Testing Study (GaTHER): An evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia. Am J Surg Pathol 2012; 36: 577-582.
11. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18-43.
12. Chen C, Yang JM, Hu TT, et al. Prognostic role of human epidermal growth factor receptor in gastric cancer: A systematic review and meta-analysis. Arch Med Res 2013; 44: 380-389.
13. Jorgensen JT,. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010; 78: 26-33.
14. Gravalos C, Jimeno A,. HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19: 1523-1529.
15. Duarte I, Llanos O,. Patterns of metastases in intestinal and diffuse types of carcinoma of the stomach. Hum Pathol 1981; 12: 237-242.
16. Koss LG, Domagala W,. Configuration of surfaces of human cancer cells in effusions. A review. Scan Electron Microsc 1980; 3: 89-100.
17. Scaltriti M, Rojo F, Ocana A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007; 99: 628-638.
18. Lemoine NR, Jain S, Silvestre F, et al. Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br J Cancer 1991; 64: 79-83.
19. Kameda T, Yasui W, Yoshida K, et al. Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. Cancer Res 1990; 50: 8002-8009.
20. Bozzetti C, Negri FV, Lagrasta CA, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 2011; 104: 1372-1376.
21. Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009; 40: 769-777.
22. Reichelt U, Duesedau P, Tsourlakis M, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007; 20: 120-129.
23. Lee S, de Boer WB, Fermoyle S, Platten M, Kumarasinghe MP,. Human epidermal growth factor receptor 2 testing in gastric carcinoma: Issues related to heterogeneity in biopsies and resections. Histopathology 2011; 59: 832-840.